BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34556022)

  • 1. Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients.
    Liu B; Liu Z; Wang Y; Lian X; Han Z; Cheng X; Zhu Y; Liu R; Zhao Y; Gao Y
    Mol Med; 2021 Sep; 27(1):117. PubMed ID: 34556022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GINS complex subunit 4, a prognostic biomarker and reversely mediated by Krüppel-like factor 4, promotes the growth of colorectal cancer.
    Rong Z; Luo Z; Zhang J; Li T; Zhu Z; Yu Z; Fu Z; Qiu Z; Huang C
    Cancer Sci; 2020 Apr; 111(4):1203-1217. PubMed ID: 32012389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GINS4 might be a novel prognostic immune-related biomarker of not only esophageal squamous cell carcinoma and other cancers.
    Jin D; Yuan L; Li F; Wang S; Mao Y
    BMC Med Genomics; 2022 Apr; 15(1):75. PubMed ID: 35365175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
    Wang Y; Zhao W; Liu X; Guan G; Zhuang M
    J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
    Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
    Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and prognosis analysis of GINS subunits in human breast cancer.
    Li H; Cao Y; Ma J; Luo L; Ma B
    Medicine (Baltimore); 2021 Mar; 100(11):e24827. PubMed ID: 33725952
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients.
    Liu Z; Zhang W; Cheng X; Wang H; Bian L; Wang J; Han Z; Wang Y; Lian X; Liu B; Ren Z; Zhang B; Jiang Z; Lin Z; Gao Y
    Mol Med; 2021 May; 27(1):52. PubMed ID: 34051735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
    Li J; Zhang Y; Qu Z; Ding R; Yin X
    Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
    Lvu W; Fei X; Chen C; Zhang B
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
    Xu H; Chai S; Wang Y; Wang J; Xiao D; Li J; Xiong N
    CNS Neurosci Ther; 2020 Aug; 26(8):804-814. PubMed ID: 32678519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significantly high expression of NUP37 leads to poor prognosis of glioma patients by promoting the proliferation of glioma cells.
    Liu Z; Wang H; Jia Y; Wang J; Wang Y; Bian L; Liu B; Lian X; Zhang B; Ren Z; Zhang W; Dai W; Gao Y
    Cancer Med; 2021 Aug; 10(15):5218-5234. PubMed ID: 34264013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CBX3 promotes glioma U87 cell proliferation and predicts an unfavorable prognosis.
    Zhao SP; Wang F; Yang M; Wang XY; Jin CL; Ji QK; Li S; Zhao XL
    J Neurooncol; 2019 Oct; 145(1):35-48. PubMed ID: 31502042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.
    Thota B; Arimappamagan A; Kandavel T; Shastry AH; Pandey P; Chandramouli BA; Hegde AS; Kondaiah P; Santosh V
    J Neurosurg; 2014 Aug; 121(2):374-83. PubMed ID: 24878287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma.
    Zhang Z; Chen P; Xie H; Cao P
    Front Oncol; 2021; 11():654185. PubMed ID: 33842367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.